Virpax Pharmaceuticals Inc's Customers Performance

Name: Virpax Pharmaceuticals Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

VRPX

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


VRPX's Source of Revenues		• List of VRPX Customers

for the same period Virpax Pharmaceuticals Inc

• List of VRPX Customers

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Virpax Pharmaceuticals Inc's Comment on Sales, Marketing and Customers

News about Virpax Pharmaceuticals Inc Contracts

Virpax Pharmaceuticals Advances Pain Management Innovation Positive Results from Probudur Dose Range Finding Stu...

In a significant stride toward innovative pain management solutions, Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX), a corporation dedicated to developing non-addictive therapeutic options for a variety of conditions including pain management, post-traumatic stress disorder (PTSD), and central nervous system (CNS) disorders, has unveiled encouraging findings from a minipig Dose Range Finding (DRF) study for its flagship product, Probudur. Probudur is a long-acting liposomal formulation of bupivacaine, designed to be injected directly at the site of a surgical wound. This cutting-edge formulation aims to provide not only immediate analgesia but also prolonged pain relief, catering to patients in need of effectiv...

Virpax Strengthens its Commitment to Pain Management Solutions with Extended Collaboration with U.S. Health Agencies

In a significant advancement for pain management, Virpax Pharmaceuticals Inc. (Nasdaq: VRPX) has announced the extension of its cooperative research and development agreement with the National Center for Advancing Translational Sciences (NCATS), a distinguished entity of the National Institutes of Health (NIH) under the U.S. Department of Health and Human Services. This strategic extension marks a pivotal step in Virpax s mission to bolster the development of their innovative NES100 product, which is aimed at providing alternative solutions for acute and chronic non-cancer pain.Virpax, a company specializing in pain management therapy development, is leveraging its expertise to explore alternative treatments...

VRPX's Stock Performance relative to it's Customers

VRPX's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Virpax Pharmaceuticals Inc	0.00	0.00	-12.07	5
SUBTOTAL	0.00	0.00	0.00	-

Sources: Virpax Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Virpax Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Virpax Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.